Drug intelligence / Profile preview

ZMP201

Development stage: Preclinical
Lead developer: Zymedi
Modality: Vaccines & Immunotherapeutics

Overview

ZMP201 (also known as C-VAX) is a vaccine adjuvant platform developed by Zymedi that targets the Toll-like receptor 2/6 (TLR2/6) heterodimer. By acting as an agonist for these receptors, ZMP201 stimulates the innate immune system to enhance the potency and duration of immune responses to vaccine antigens. The platform is currently in clinical development for use in both anti-cancer and antiviral vaccine applications, where it is intended to boost the efficacy of the associated vaccine candidates.

Other names: C-VAX

Targets

TLR2 (Toll-like Receptor 2)TLR6

Beyond the preview

Go deeper on ZMP201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZMP201.

Explore the full profile